Source: Health Products Regulatory Authority (IE) Revision Year: 2018 Publisher: Mercury Pharmaceuticals (Ireland) Ltd, 4045 Kingswood Road, Citywest Business Park, Co Dublin, Ireland
Pharmacotherapeutic group: Antithrombotic agents, Vitamin K antagonists
ATC code: B01AA03
Warfarin is a coumarin anti-coagulant. By depressing the hepatic Vitamin K-dependent synthesis of coagulation factors II (prothrombin) VII, IX and X, warfarin can prevent venous thrombosis and embolisation, although it has no direct effect on an established thrombus.
Warfarin sodium is readily absorbed from the gastro-intestinal tract. It can also be absorbed through the skin.
It is extensively bound to plasma proteins and its plasma half life is about 37 hours. It crosses the placenta but does not occur in significant quantities in breast milk.
Warfarin is metabolised by hepatic microsomal enzymes to inactive metabolites.
Inactive metabolites are excreted in urine and stool.
No further relevant information other than that which is included in other sections of the Summary of Product Characteristics.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
